SoftOx Solutions AS
OOSL:SOFTX0.11
NOK
+0.00
(-1.04%)
ISIN
NO0010811961
Return %
Stock
S&P 500
1Y
53.37
14.20
3Y
-89.73
81.12
5Y
-99.09
68.34
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Quarterly Revenue
NOK
•
in mil. unless spec.Quarterly Earnings Per Share
NOK
•
in mil. unless spec.Quarterly Dividends Per Share
NOK
•
in mil. unless spec.Company Description
- CEO
- Thomas Bjarnsholt
- Full Time Employees
- 2
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Oslo Norway
- IPO Date
- Jun 1, 2018
- Website
- soft-ox.com
- Similar Companies
- Business
- SoftOx Solutions AS is a clinical-stage biotechnology and medical technology company headquartered in Oslo, Norway, specializing in the development of antimicrobial and antiseptic solutions designed to combat infectious diseases, facilitate wound healing, and address antimicrobial resistance. Founded in 2012 and listed on Euronext Growth Oslo under the ticker SOFTX, the company leverages a proprietary, synthetic hypohalous acid chemistry platform that generates stable, highly potent oxidant formulations capable of eradicating microbial biofilms and broad-spectrum pathogens without inducing bacterial resistance or cellular cytotoxicity. The company's primary products and pipeline candidates encompass four core segments: wound care, respiratory therapeutics, surface and skin disinfection, and veterinary healthcare. In the wound care sector, SoftOx Solutions develops the SoftOx Biofilm Eradicator (SBE), an advanced wound irrigation solution engineered to disrupt and eliminate complex bacterial biofilms in chronic wounds such as diabetic foot ulcers and venous leg ulcers; the SoftOx Wound Irrigation Solution (SWIS), formulated for acute wound cleansing, surgical debridement, and infection prevention; and associated antimicrobial hydrogel dressings. In the respiratory therapy segment, the company offers the SoftOx Inhalation Solution (SIS), an inhalable aerosolized antimicrobial treatment intended to treat viral, bacterial, and fungal respiratory tract infections, including pneumonia, chronic obstructive pulmonary disease exacerbations, and viral respiratory pathogens. In the infection prevention and antisepsis segment, the company provides alcohol-free, non-toxic topical antiseptics and hospital-grade surface disinfectants under brand designations including SafeDes, designed for healthcare institutions, industrial environments, and consumer hygiene. Additionally, the company develops veterinary antimicrobial rinses, topicals, and herd health formulations for livestock, companion animals, and aquaculture through dedicated animal health initiatives. SoftOx Solutions AS serves healthcare providers, clinical hospitals, specialized wound care centers, emergency medical units, defense and military organizations, veterinary institutions, and commercial disinfection distributors. The company conducts its research, clinical trials, and regulatory compliance activities primarily in Norway and across broader European markets, operating through specialized functional units and subsidiaries, including SoftOx Defense Solutions AS and SoftOx Animal Health. In recent operational and corporate developments, SoftOx Solutions AS has implemented a series of strategic reorganizations, refinancing programs, and pipeline prioritizations to streamline operations and accelerate commercialization. The company secured funding and consortium participation under the European Defence Fund to advance battlefield wound care solutions for military and emergency field operations, collaborating with European defense and medical partners. Furthermore, SoftOx Solutions restructured its operational cost base, executed private placements and convertible debt facilities to strengthen working capital, and aligned its clinical development priorities toward obtaining European Medical Device Regulation (MDR) certification and advancing clinical trials for its chronic wound and inhalation platforms. The company has also realigned its commercial strategy toward regional distribution and licensing agreements to monetize its infection prevention and animal health assets while focusing internal resources on advanced clinical therapeutics.